Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
作者： Peter K. Schädlich , Josef Georg Brecht , Badrudin Rangoonwala , Eduard Huppertz
DOI: 10.2165/00019053-200422150-00001
关键词:
摘要: Background: In the HOPE (Heart Outcomes Prevention Evaluation) trial, ramipril (compared with placebo) significantly reduced cardiovascular death and all-cause mortality as well incidence of costly events, such myocardial infarction, revascularisation, stroke, cardiac arrest, hospitalisation due to heart failure worsening angina pectoris, new-onset diabetes mellitus microvascular diabetic complications.
springer.com
sci-hub.se 参考文章(51)
Douglas Coyle, Keith Tolley, None, Discounting of health benefits in the pharmacoeconomic analysis of drug therapies: an issue for debate? PharmacoEconomics. ,vol. 2, pp. 153- 162 ,(1992) , 10.2165/00019053-199202020-00007
Effects of an angiotensin-converting -enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients The New England Journal of Medicine. ,vol. 342, pp. 145- 153 ,(2000) , 10.1056/NEJM200001203420301
David Wood, Guy De Backer, Ole Faergeman, Ian Graham, Giuseppe Mancia, Kalevi Pyörälä, Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis. ,vol. 140, pp. 199- 270 ,(1998) , 10.1016/S0021-9150(98)90209-X
K. PYÖRÄLÄ, G. DE BACKER, I. GRAHAM, P. POOLE-WILSON, D. WOOD, Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. European Heart Journal. ,vol. 15, pp. 1300- 1331 ,(1994) , 10.1093/OXFORDJOURNALS.EURHEARTJ.A060388
J.Robert Beck, Stephen G. Pauker, Jonathan E. Gottlieb, Karen Klein, Jerome P. Kassirer, A convenient approximation of life expectancy (the “DEALE”): II. Use in medical decision-making The American Journal of Medicine. ,vol. 73, pp. 889- 897 ,(1982) , 10.1016/0002-9343(82)90787-2
B.H.R. Wolffenbuttel, Hope Hope Study Investigators, Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy The Lancet. ,vol. 22, pp. 253- 259 ,(2000)
Peter K. Schädlich, Josef Georg Brecht, Massimo Brunetti, Eva Pagano, Badrudin Rangoonwala, Eduard Huppertz, Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. PharmacoEconomics. ,vol. 19, pp. 497- 512 ,(2001) , 10.2165/00019053-200119050-00005
Ronald L. Wasserstein, Monte Carlo: Concepts, Algorithms, and Applications Technometrics. ,vol. 39, pp. 338- 338 ,(1997) , 10.1080/00401706.1997.10485133
Salim Yusuf, Hertzel Gerstein, Byron Hoogwerf, Janice Pogue, Jackie Bosch, Bruce HR Wolffenbuttel, Bernard Zinman, HOPE Study Investigators, HOPE Study Investigators, None, Ramipril and the Development of Diabetes JAMA. ,vol. 286, pp. 1882- 1885 ,(2001) , 10.1001/JAMA.286.15.1882
Andre Lamy, Salim Yusuf, Janice Pogue, Amiram Gafni, Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study Circulation. ,vol. 107, pp. 960- 965 ,(2003) , 10.1161/01.CIR.0000050600.49419.25